Medigene

Medigene EBITDA

Delisted·Jul 2, 2026

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medigene (MDG1.DE) as of Oct 19, 2026 is -14.64 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 12.93 M EUR — a change of -213.20% (lower).

EBITDA

-14.64 MEUR

YoY

-213.20%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medigene is 2023 -14.64 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medigene was 2022 12.93 M EUR. It decreases by -213.20% lower compared to the previous year.

The Medigene EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2016
-8.26 M EUR
Jan 1, 2017
-12.19 M EUR
Jan 1, 2018
-16.29 M EUR
Jan 1, 2019
-18.15 M EUR
Jan 1, 2020
-19.14 M EUR
Jan 1, 2021
-6.69 M EUR
Jan 1, 2022
12.93 M EUR
Jan 1, 2023
-14.64 M EUR
The Medigene EBITDA history
YEAREBITDAYoY
-14.64 MEUR-213.20%
12.93 MEUR-293.32%
-6.69 MEUR-65.05%
-19.14 MEUR+5.48%
-18.15 MEUR+11.37%
-16.29 MEUR+33.66%
-12.19 MEUR+47.61%
-8.26 MEUR-13.05%
-9.50 MEUR+358.57%
-2.07 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Medigene Stock analysis

What does Medigene do? Medigene AG, based in Planegg, Germany, is a biotechnology company specializing in developing innovative cancer treatment platforms. The company focuses on personalized T cell-based immunotherapies, including TCR-modified T cells for adoptive therapy, dendritic cell vaccines for low tumor burdens, and T-cell-specific monoclonal antibodies. It operates offices in Martinsried, Germany, and in Washington DC and San Diego, USA, with 136 employees. Medigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medigene stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medigene is -14.64 M EUR in 2023.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Medigene changed from 12.93 M EUR to -14.64 M EUR, representing a -213.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Medigene since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Medigene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Medigene

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Medigene